Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy 4D Molecular Therapeutics Inc stock

Learn how to easily invest in 4D Molecular Therapeutics Inc stock.

4D Molecular Therapeutics Inc is a biotechnology business based in the US. 4D Molecular Therapeutics Inc shares (FDMT) are listed on the NASDAQ and all prices are listed in US Dollars. 4D Molecular Therapeutics Inc employs 140 staff and has a trailing 12-month revenue of around $2 million.

How to buy 4D Molecular Therapeutics Inc stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – FDMT. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Easy to use platform with low fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

4D Molecular Therapeutics Inc stock price (NASDAQ: FDMT)

Use our graph to track the performance of FDMT stocks over time.

4D Molecular Therapeutics Inc shares at a glance

Information last updated 2023-02-01.
Latest market close$21.70
52-week range$5.32 - $26.49
50-day moving average $21.92
200-day moving average $12.18
Wall St. target price$38.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.79

Buy 4D Molecular Therapeutics Inc stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$10
FINDER EXCLUSIVE: Get $15
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy 4D Molecular Therapeutics Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

4D Molecular Therapeutics Inc price performance over time

Historical closes compared with the close of $21.7 from 2023-02-06

1 week (2023-01-31) 3.09%
1 month (2023-01-06) -6.43%
3 months (2022-11-08) 167.57%
6 months (2022-08-08) 92.89%
1 year (2022-02-08) 18.51%
2 years (2021-02-08) -55.03%
3 years (2020-02-04) N/A
5 years (2018-02-04) N/A

4D Molecular Therapeutics Inc financials

Revenue TTM $2 million
Gross profit TTM $-43,322,000
Return on assets TTM -25.46%
Return on equity TTM -44.24%
Profit margin 0%
Book value $7.76
Market capitalisation $695.8 million

TTM: trailing 12 months

4D Molecular Therapeutics Inc share dividends

We're not expecting 4D Molecular Therapeutics Inc to pay a dividend over the next 12 months.

4D Molecular Therapeutics Inc share price volatility

Over the last 12 months, 4D Molecular Therapeutics Inc's shares have ranged in value from as little as $5.32 up to $26.49. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 4D Molecular Therapeutics Inc's is 2.7511. This would suggest that 4D Molecular Therapeutics Inc's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put 4D Molecular Therapeutics Inc's beta into context you can compare it against those of similar companies.

4D Molecular Therapeutics Inc overview

4D Molecular Therapeutics, Inc. , a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF.

Frequently asked questions

What percentage of 4D Molecular Therapeutics Inc is owned by insiders or institutions?
Currently 11.508% of 4D Molecular Therapeutics Inc shares are held by insiders and 82.16% by institutions.
How many people work for 4D Molecular Therapeutics Inc?
Latest data suggests 140 work at 4D Molecular Therapeutics Inc.
When does the fiscal year end for 4D Molecular Therapeutics Inc?
4D Molecular Therapeutics Inc's fiscal year ends in December.
Where is 4D Molecular Therapeutics Inc based?
4D Molecular Therapeutics Inc's address is: 5858 Horton Street, EmeryVille, CA, United States, 94608
What is 4D Molecular Therapeutics Inc's ISIN number?
4D Molecular Therapeutics Inc's international securities identification number is: US35104E1001

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site